Armodafinil - Teva Pharmaceutical Industries
Alternative Names: CEP-10953; Nuvigil; R-modafinilLatest Information Update: 04 Jan 2024
At a glance
- Originator Cephalon
- Developer Cephalon; Lindner Center of HOPE; Oncotherapeutics.; Teva Pharmaceutical Industries
- Class Acetamides; Benzhydryl compounds; Sleep disorder therapies; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor agonists; Biogenic amine receptor agonists; Catecholamine receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypersomnia
- Phase III Eating disorders
- Discontinued Bipolar depression; Fatigue; Schizophrenia
Most Recent Events
- 04 Jan 2024 Discontinued - Phase-III for Fatigue in USA (PO) (NDR batch #30)
- 16 Apr 2021 No development reported - Phase-III for Fatigue in USA (PO) (NCT01160380)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hypersomnia(In adolescents, In children) in Finland (PO, Tablet)